There are potential risks from diminished renal function when administering immunoglobulin (IG). Therefore, clinicians should evaluate all patients receiving IG for underlying chronic kidney disease (CKD)/renal impairment on a regular basis; this is of critical importance in patients receiving high-dose IG. If CKD/renal impairment is identified, patients receiving IG should be closely monitored and managed to prevent further renal damage. Identification of the cause of CKD/renal impairment is strongly encouraged, as IG therapy may need to be modified.
Learning Objectives:
After attending this activity, the learner will have a greater awareness of the prevalence of CKD/renal impairment in the general population and, more specifically, in patients currently receiving, or planning to receive, IG therapy.
After attending this activity, the learner will have the tools needed to successfully screen patients for potential CKD/renal impairment who are currently receiving, or are planning to receive, IG therapy.
If renal disease is identified, learners will be given specific recommendations for monitoring and managing patients with CKD/renal impairment who are currently receiving, or are planning to receive, IG therapy